Minot Light Capital, an investment management firm, recently released its fourth-quarter 2024 investor letter. A copy of the ...

The CEO of Germany's Merck KGaA on Thursday said a recovery in sales growth at its existing business means it can take a ...

Financial writer analysis of Arcutis Biotherapeutics, Inc. stock surge and potential growth, FDA approvals, and partnerships ...

Is BioMarin stock a bargain or a falling knife? Learn about key issues affecting its investment prospects and potential for recovery.

Johnson & Johnson ( JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to ...

Johnson & Johnson , fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular , reported fourth-quarter ...

Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and ...

Rhythm Pharmaceuticals (NASDAQ:RYTM) reported its third-quarter 2024 earnings, highlighting a steady increase in revenue and strategic developments in product innovation and market expansion. Despite ...

Welcome to “Sector Spotlight,” where The Fly looks at a new industry every week and highlights its happenings. Stay Ahead of the ...

The Department of Health and Human Services, Office of Inspector General (“OIG”) recently released a favorable advisory opinion, OIG Advisory ...

Kite Pharma is flying high with the addition of a new member to its senior leadership team. | Kite Pharma is flying high with ...

Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine ...